FindTrial
Sign In

OPEN PILOT STUDY, TWO ARMS, WITH HISTORIC CONTROL, MULTICENTRIC TO EVALUATE SAFETY AND EFFICACY OF ASSOCIATION WITH EVEROLIMUS AND LOW DOSES OF CYCLOSPORIN AND STEROIDS AFTER INDUCTION WITH MONOCLONAL ANTIBODY ANTI CD25 IN PEDIATRIC PATIENTS AFTER KIDNEY TRANSPLANTS - ND

OPEN PILOT STUDY, TWO ARMS, WITH HISTORIC CONTROL, MULTICENTRIC TO EVALUATE SAFETY AND EFFICACY OF ASSOCIATION WITH EVEROLIMUS AND LOW DOSES OF CYCLOSPORIN AND STEROIDS AFTER INDUCTION WITH MONOCLONAL ANTIBODY ANTI CD25 IN PEDIATRIC PATIENTS AFTER KIDNEY TRANSPLANTS - ND

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2008-006729-15-IT
Enrollment
Unknown
Registered
2008-12-19
Start date
2008-11-25
Completion date
Unknown
Last updated
2012-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric patient after kidney transplant MedDRA version: 9.1 Level: LLT Classification code 10023439 Term: Kidney transplant rejection

Interventions

Trade Name: CERTICAN Pharmaceutical Form: Tablet INN or Proposed INN: Everolimus Concentration unit: mg milligram(s) Concentration type: equal Concentration number: .25-

Sponsors

ISTITUTO GIANNINA GASLINI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Age=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Systemic infection before starting everolimus

Design outcomes

Primary

MeasureTime frame
Main Objective: Efficacy;Secondary Objective: Safety;Primary end point(s): % failure—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026